"目录号: HY-13859
Anti-infection-
Clevudine能抗乙肝病毒。
HBV
相关产品
Tenofovir Disoproxil Fumarate-Squalamine-Merimepodib-Entecavir monohydrate-Adefovir dipivoxil-Bay 41-4109-Bicyclol-Telbivudine-Osalmid-Helioxanthin 8-1-Helioxanthin derivative 5-4-2-Lagociclovir-Oxethazaine-
生物活性
Description
Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].
Clinical Trial
NCT00558493
Bukwang Pharmaceutical
Chronic Hepatitis B
November 2007
Phase 4
NCT00044135
Triangle Pharmaceuticals
Hepatitis B
August 2002
Phase 2
NCT00823342
French National Agency for Research on AIDS and Viral Hepatitis-Gilead Sciences-Pharmasset
HBe Negative Chronic Hepatitis B-Hepatitis B Viral Infection
December 2008
Phase 3
NCT00558818
Bukwang Pharmaceutical
Chronic Hepatitis B
June 2007
Phase 4
NCT01264094
Bukwang Pharmaceutical
Chronic Hepatitis B
November 2009
Phase 4
NCT00362700
Bukwang Pharmaceutical
Hepatitis B
July 2003
Phase 2
NCT00672867
Bukwang Pharmaceutical
Patients With LC-B
December 2007
Phase 3
NCT00305019
Bukwang Pharmaceutical
Hepatitis B
July 2002
Phase 2
NCT00313287
Bukwang Pharmaceutical
Hepatitis B
June 2003
Phase 3
NCT00313274
Bukwang Pharmaceutical
Hepatitis B
July 2003
Phase 3
NCT00362505
Bukwang Pharmaceutical
Hepatitis B
June 2004
Phase 3
NCT01264354
Bukwang Pharmaceutical
Chronic Hepatitis B
March 2010
Phase 4
NCT01264133
Bukwang Pharmaceutical
Chronic Hepatitis B
September 2009
Phase 4
NCT01264367
Bukwang Pharmaceutical
HBeAg(+) Chronic Hepatitis B
December 2008
Phase 4
NCT01263002
Bukwang Pharmaceutical
Hepatitis B Associated Hepatocellular Carcinoma
June 2010
Phase 4
NCT00362635
Bukwang Pharmaceutical
Hepatitis B
August 2006
Phase 3
NCT00313261
Bukwang Pharmaceutical
Hepatitis B
June 2003
Phase 2
NCT00501124
Bukwang Pharmaceutical
Hepatitis B
May 2007
Phase 4
NCT01266005
Bukwang Pharmaceutical
Chronic Hepatitis B
August 2009
Phase 4
NCT00641082
Bukwang Pharmaceutical
HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
February 2008
Phase 4
NCT00798460
Inje University-Bukwang Pharmaceutical
Chronic Hepatitis B
December 2008
Phase 4
NCT01192854
Eisai Co., Ltd.-Eisai Inc.
Chronic Hepatitis B
February 2010
Phase 3
NCT00496158
Pharmasset
Chronic Hepatitis-Hepatitis B
August 2007
Phase 3
NCT00496002
Pharmasset
Chronic Hepatitis-Hepatitis B
August 2007
Phase 3
NCT01581242
Bukwang Pharmaceutical
Healthy
April 2012
Phase 1
NCT01712815
University of Southern California-National Cancer Institute (NCI)
HER2-positive Breast Cancer-Recurrent Breast Cancer-Stage IA Breast Cancer-Stage IB Breast Cancer-Stage II Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer-Stage IV Breast Cancer
November 22, 2013
View MoreCollapse
References
[1].Lee, H.S., et al., A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2006. 43(5): p. 982-8.
[2].Jang, J.H., et al., Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat, 2011. 18(2): p. 84-90.